Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ECO Animal Health Group plc (EAH.L)
GBp88.50
+2.50 (+2.91%)
GB LSE Healthcare Drug Manufacturers - Specialty & Generic
Address
78 Coombe Road KT3 4QS
New Malden, GB
New Malden, GB
CEO
David Charles Hallas
Website
ecoanimalhealthgroupplc.com
IPO
1995-09-26
ISIN GB0032036807
Description
ECO Animal Health Group plc, established in 1972 and based in New Malden, United Kingdom, focuses on the worldwide research, regulatory approval, and distribution of veterinary pharmaceutical solutions. The company's offerings include Aivlosin, a macrolide antibiotic specifically formulated to address digestive and respiratory illnesses in pigs and poultry. Additionally, its product range encompasses various generic drugs like Ecomectin, Ecoheart, Ecotraz, and Ecomintic. These endectocides and other antiparasitics are designed to manage and prevent parasitic infestations such as worms, ticks, and lice across a diverse array of animals, including cattle, sheep, pigs, horses, and dogs. ECO Animal Health Group also provides Chlortetracycline and Oxytetracycline for treating bacterial infections in swine, fowl, and bovine animals.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
GBp88.50
+2.50 (+2.91%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
74.1K
Beta
0.00
Float Shares
59.42M
Free Float %
87.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.52% | -1.55% | +2.69% | -9.48% | +1.60% | -8.61% | +56.56% | -15.86% | -73.84% | -75.51% | +37.74% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
88.50
DCF (Unlevered)
151.96
+71.7%
DCF (Levered)
407.54
+360.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 5 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.30
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
4 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
3 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-11.0% Q3'25: +3.7% (vs Q3'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+59.9% ★ Q3'25: +72.0% (vs Q3'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+9.4% ★ Q3'25: -2.8% (vs Q3'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+5.6% Q3'25: +3.0% (vs Q3'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+4.0% Q3'25: +4.1% (vs Q3'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.5% Q3'25: +0.1% (vs Q3'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.52× ★ Q3'25: 0.49× (vs Q3'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2006 actual |
Mar 2007 actual |
Mar 2008 actual |
Mar 2010 actual |
Mar 2011 actual |
Mar 2012 actual |
Mar 2013 actual |
Mar 2014 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 5 Rev. Ana. 4 EPS Ana. |
Mar 2027 6 Rev. Ana. 4 EPS Ana. |
Mar 2028 6 Rev. Ana. 4 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
20.33M
est: 20.55M (-1.1%)
|
14.70M
est: 18.68M (-21.3%)
|
16.48M
est: 18.27M (-9.8%)
|
21.77M
est: 22.53M (-3.4%)
|
27.08M
est: 28.72M (-5.7%)
|
28.32M
est: 30.45M (-7.0%)
|
28.99M
est: 32.68M (-11.3%)
|
31.87M
est: 36.24M (-12.1%)
|
39.00M
est: 38.30M (+1.8%)
|
47.14M
est: 44.30M (+6.4%)
|
61.42M
est: 59.81M (+2.7%)
|
67.20M
est: 69.40M (-3.2%)
|
67.25M
est: 75.81M (-11.3%)
|
72.11M
est: 70.76M (+1.9%)
|
105.61M
est: 100.83M (+4.7%)
|
82.20M
est: 81.30M (+1.1%)
|
85.31M
est: 84.70M (+0.7%)
|
89.42M
est: 89.47M (-0.1%)
|
79.60M
est: 82.78M (-3.8%)
|
85.92M
85.64M – 86.00M
+3.8% YoY
|
89.82M
87.04M – 92.47M
+4.5% YoY
|
94.13M
93.69M – 94.58M
+4.8% YoY
|
94.00M
91.08M – 96.77M
-0.1% YoY
|
| EBITDA |
3.32M
est: 1.94M (+71.2%)
|
2.20M
est: 1.89M (+16.3%)
|
1.79M
est: 1.69M (+5.9%)
|
5.12M
est: 2.09M (+145.7%)
|
5.87M
est: 2.66M (+120.8%)
|
6.10M
est: 2.82M (+116.6%)
|
6.11M
est: 3.02M (+101.9%)
|
6.48M
est: 3.35M (+93.2%)
|
8.32M
est: 3.64M (+128.4%)
|
10.37M
est: 4.21M (+146.1%)
|
16.29M
est: 13.74M (+18.6%)
|
17.61M
est: 18.77M (-6.2%)
|
12.66M
est: 16.41M (-22.9%)
|
7.60M
est: 11.12M (-31.6%)
|
18.63M
est: 11.33M (+64.5%)
|
3.62M
est: 12.64M (-71.3%)
|
7.41M
est: 13.57M (-45.4%)
|
6.53M
est: 8.43M (-22.5%)
|
7.29M
est: 7.81M (-6.7%)
|
8.11M
8.08M – 8.12M
+3.8% YoY
|
8.48M
8.22M – 8.73M
+4.5% YoY
|
8.89M
8.84M – 8.93M
+4.8% YoY
|
8.87M
8.60M – 9.13M
-0.1% YoY
|
| EBIT |
281.0K
est: 1.39M (-79.7%)
|
468.0K
est: 290.8K (+61.0%)
|
-595.5K
est: 1.21M (-149.3%)
|
2.11M
est: 1.49M (+41.7%)
|
2.54M
est: 1.90M (+34.0%)
|
2.41M
est: 2.01M (+19.8%)
|
3.36M
est: 2.16M (+55.4%)
|
3.72M
est: 2.39M (+55.3%)
|
5.59M
est: 2.60M (+115.1%)
|
7.71M
est: 3.01M (+156.4%)
|
13.45M
est: 10.09M (+33.3%)
|
13.88M
est: 14.67M (-5.4%)
|
10.07M
est: 15.41M (-34.7%)
|
6.14M
est: 8.81M (-30.3%)
|
19.45M
est: 8.97M (+116.8%)
|
1.67M
est: 10.01M (-83.3%)
|
4.95M
est: 10.75M (-54.0%)
|
3.74M
est: 6.02M (-37.9%)
|
4.46M
est: 5.58M (-20.0%)
|
5.79M
5.77M – 5.80M
+3.8% YoY
|
6.05M
5.87M – 6.23M
+4.5% YoY
|
6.34M
6.31M – 6.37M
+4.8% YoY
|
6.34M
6.14M – 6.52M
-0.1% YoY
|
| Net Income |
-42.0K
est: 3.76M (-101.1%)
|
2.82M
est: 54.5K (+5,072.6%)
|
-784.0K
est: 3.70M (-121.2%)
|
1.24M
est: 1.90M (-34.9%)
|
1.59M
est: 5.57M (-71.4%)
|
2.22M
est: 2.96M (-25.1%)
|
2.62M
est: 2.38M (+9.8%)
|
2.43M
est: 4.38M (-44.5%)
|
4.09M
est: 7.01M (-41.6%)
|
6.04M
est: 8.48M (-28.8%)
|
10.57M
est: 8.15M (+29.6%)
|
9.32M
est: 12.26M (-24.0%)
|
7.25M
est: 10.17M (-28.7%)
|
3.90M
est: 7.00M (-44.3%)
|
7.34M
est: 7.12M (+3.0%)
|
-686.0K
est: 7.95M (-108.6%)
|
1.01M
est: 1.01M (+0.0%)
|
1.05M
est: 1.05M (+0.0%)
|
1.69M
est: 1.11M (+51.5%)
|
2.06M
1.56M – 2.87M
+84.7% YoY
|
2.42M
1.33M – 3.05M
+17.9% YoY
|
2.76M
1.65M – 3.41M
+14.0% YoY
|
2.36M
2.27M – 2.45M
-14.6% YoY
|
| SGA |
3.49M
est: 6.13M (-43.2%)
|
4.70M
est: 5.41M (-13.0%)
|
3.61M
est: 5.34M (-32.4%)
|
3.80M
est: 7.79M (-51.2%)
|
4.65M
est: 8.40M (-44.6%)
|
5.13M
est: 8.93M (-42.5%)
|
9.75M
est: 9.56M (+2.0%)
|
8.08M
est: 10.81M (-25.3%)
|
9.50M
est: 11.26M (-15.7%)
|
11.11M
est: 13.31M (-16.6%)
|
14.52M
est: 18.79M (-22.7%)
|
14.81M
est: 17.37M (-14.7%)
|
11.58M
est: 16.50M (-29.8%)
|
17.13M
est: 13.82M (+24.0%)
|
26.57M
est: 14.07M (+88.8%)
|
20.41M
est: 15.71M (+30.0%)
|
25.78M
est: 16.86M (+52.9%)
|
29.39M
est: 26.66M (+10.3%)
|
28.73M
est: 24.69M (+16.3%)
|
25.63M
25.55M – 25.66M
+3.8% YoY
|
26.80M
25.97M – 27.59M
+4.5% YoY
|
28.08M
27.95M – 28.22M
+4.8% YoY
|
28.04M
27.17M – 28.87M
-0.1% YoY
|
| EPS |
0.00
est: 0.05 (-102.6%)
|
0.09
est: 0.04 (+136.2%)
|
-0.02
est: 0.05 (-143.6%)
|
0.03
est: 0.03 (-6.5%)
|
0.03
est: 0.08 (-61.9%)
|
0.04
est: 0.04 (-2.0%)
|
0.05
est: 0.11 (-53.5%)
|
0.04
est: 0.06 (-32.0%)
|
0.07
est: 0.10 (-31.8%)
|
0.10
est: 0.12 (-19.8%)
|
0.16
est: 0.16 (-2.0%)
|
0.14
est: 0.20 (-30.3%)
|
0.11
est: 0.20 (-45.8%)
|
0.06
est: 0.05 (+15.2%)
|
0.11
est: 0.11 (-0.6%)
|
-0.01
est: 0.05 (-120.6%)
|
0.01
est: 0.03 (-41.6%)
|
0.02
est: 0.02 (-25.0%)
|
0.02
est: 0.02 (+51.4%)
|
0.03
0.02 – 0.04
+81.5% YoY
|
0.03
0.02 – 0.04
+7.7% YoY
|
0.04
0.02 – 0.05
+22.5% YoY
|
0.03
0.03 – 0.04
-13.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-01 | A | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 2/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 2/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 2/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 2/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
13.93M
OE per share TTM
0.20
Owner's Yield
21.53%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
7.4%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
19.7K
Shares Outstanding
67.76M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David Charles Hallas | Chief Executive Officer & Director | 431.0K | male |
| Christopher Wilks | Chief Financial Officer, Finance Director, Secretary & Director | 367.0K | male |
| Andrew Buglass | Chief Commercial Officer | — | male |
| Andrew Winder | Head of Business Development | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EAH.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
